DailyIQ
Last updatedUpdating…

TMO·Thermo Fisher Scientific Inc.

$673.30
+10.26 (+1.55%)
After Hours
High
$681.50
Open
$664.01
Market Cap
244.85B
52W High
$683.63
Low
$659.00
P. Close
$673.30
P/E
35.15
52W Low
$435.27
Fwd P/E
24.05
DailyIQ Est.
$707.89
Inst. Ownership
42.3%
Short Interest
1.47%
Days to Cover
2.1
Div. Yield
0.28%
Next Ex-Div
~Dec 15
Div. Growth
8+ yrs
Technical Score (1D)
57
BULLISH
News Sentiment
69
BULLISH
On Oct 13, Thermo Fisher Scientific secured a Study Start‑Up Agreement with Quantum BioPharma to run a Phase 2 trial of Lucid‑MS, while also unveiling new drug development, manufacturing, and evidence‑generation solutions at CPHI Milan 2026. The company’s broadened role spans clinical trials, advanced bioprocessing, cell culture media, and real‑world evidence infrastructure, reinforcing its position as a comprehensive partner across the drug lifecycle. Earlier that same day, Lindsell Train’s Q3 2026 investor letter highlighted Thermo Fisher as a notable contributor to the fund’s performance, noting that strong earnings in July and August, driven by the biotech and pharma rebound, supported the company’s growth prospects. The letter also expressed optimism about long‑term returns amid a tech‑dominated market, despite the fund falling 1.4% in the quarter. Together, the partnership and product announcements and the investor letter suggest a strengthening of Thermo Fisher’s service portfolio and potential revenue streams, supporting a positive outlook for the company’s future earnings.
LOW TARGET
$560 -16.8%
2 analysts
MEAN TARGET
$684 +1.6%
17 analysts
HIGH TARGET
$800 +18.8%
19 analysts
PRICE RANGE
$560.00 - $800.00
SB / B / H / S / SS
11/18/7/1/1
DAILYIQ EST.
$707.89 (+5.2%)
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NYQ
Country
United States
Symbol
TMO
Description
Thermo Fisher Scientific is a global leader in scientific research and laboratory solutions, operating across North America, Europe, Asia-Pacific, and other international markets. The company's core business involves providing essential tools and services for the life sciences, analytical instruments, specialty diagnostics, and biopharma industries. Their diverse product portfolio includes reagents, instruments, and consumables used in drug discovery, disease diagnosis, and various research applications. Thermo Fisher Scientific's competitive advantage stems from its comprehensive offerings, spanning from laboratory products to advanced diagnostic solutions, and its established distribution networks, including direct sales, e-commerce, and third-party partnerships. Founded in 1956, the company is headquartered in Waltham, Massachusetts.
Bought (1Y)
0 shares
$0
Sold (1Y)
106,257.354 shares
$63.7M
JOHNSON JENNIFER M-
Award/Grant46.3 shares2026-09-26
Keith R. Alexandra-
Award/Grant46.3 shares2026-09-26
Lynch Karen S-
Award/Grant46.3 shares2026-09-26
SPERLING SCOTT M-
Award/Grant62.96 shares2026-09-26
WEISLER DION J-
Award/Grant55.56 shares2026-09-26
72/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Net Margin
15.0%
Revenue CAGR
8.8%
Current Ratio
1.89x
Debt / Equity
0.80x
Return on Equity
12.6%
Earnings Summary
Thermo Fisher Scientific, headquartered in Waltham, Massachusetts, is a global leader in scientific research and laboratory solutions, offering a broad portfolio of reagents, instruments, and consumables that serve the life sciences, analytical, specialty diagnostics, and biopharma sectors. Operating across North America, Europe, and Asia-Pacific, the company’s integrated distribution network supports its position as a key supplier to research and clinical laboratories worldwide. In the most recent quarters, Q4 2025 revenue reached $12.215 billion, up from $10.364 billion in Q1 2025, while Q3 2025 revenue was $11.122 billion, indicating a modest but steady revenue acceleration. EPS also followed a similar pattern, with Q4 2025 EPS of $6.57 versus $5.79 in Q3 2025, and Q1 2025 EPS of $5.15 versus $5.36 in Q2 2025; the company consistently beat analyst estimates in the last four quarters, with EPS exceeding forecasts in each period. Historically, TMO has maintained a YoY revenue growth trajectory of roughly 5–6% per quarter, while EPS growth has outpaced revenue, reflecting efficient cost management and pricing power; the company has repeatedly surpassed earnings estimates, even when revenue growth slowed, underscoring a resilient earnings profile. Recent news highlights include a study‑start‑up agreement with Quantum BioPharma for a Phase 2 multiple sclerosis trial, expanding its clinical research portfolio, and a modest 5% organic revenue growth in Q2 2026 that prompted analysts to question the sustainability of its high valuation; the firm’s shares rose 11% on the announcement, yet concerns about overvaluation persisted.

EPS

EstBeatMiss
$5.03$5.46$5.90$6.33$6.77Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$6.40 - -
Q2'26$6.37$6.03-5.3%
Q1'26$5.74$5.44-5.2%
Q4'25$6.51$6.57+0.9%
Q3'25$5.50$5.79+5.3%
Q2'25$5.23$5.36+2.5%

Revenue

EstBeatMiss
$10.7B$11.1B$11.5B$12.0B$12.4BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$12.1B - -
Q2'26$11.8B$12.0B+1.5%
Q1'26$11.8B$11.0B-6.7%
Q4'25$12.1B$12.2B+1.2%
Q3'25 - $11.1B -
Q2'25 - $10.9B -

Market Data

TMO Stock Snapshot

NEUTRAL57/100
$673.20−$0.10 (0.0%)
Market cap
244.85B
P/E ratio
35.1
Day range
$659.00 – $681.50
News sentiment
69/100 · Bullish
Analyst target
$683.84 (+1.6%)
Consensus
Buy · 38 analysts
52-week range+54.7% off low · -1.5% from high
$435.27$683.63
Price $673.20 DailyIQ Est. $707.89

TMO sits near its 52-week high with the technical picture unresolved. Positioning shifts among large allocators, not retail flow, set the tone for a name this size.

Reverse DCF

What growth is priced into TMO?

RICH

At today's price, Thermo Fisher Scientific Inc. needs to grow free cash flow about 26.1% a year for the next 10 years to justify its valuation at a 8.45% cost of capital. Over its actual history it has compounded free cash flow at 12.6% a year, so the market is asking for 13.5 percentage points above its own delivered rate. On that basis TMO looks priced above what its own growth record supports.

Implied FCF growth
26.1%
Historical FCF CAGR
12.6%
Growth gap
+13.5 pts
Verdict
RICH
Discount rate (WACC)
8.45%
Beta
0.83

Behaviour On Record

What TMO's own history says about today's numbers

Realized volatility (21d)
24.9% 66th pct
Below its peak
-1.8%
vs 200-day average
+22.2%
Up days (1y)
50%

Thermo Fisher Scientific Inc. is currently running 24.9% annualised volatility over the last 21 sessions. Measured against TMO's own 13 years of daily returns rather than a market-wide average, that is the 66th percentile — a little above its own norm, against a typical reading of 22.2%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

TMO is trading -1.8% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -16.6%, and the deepest was -35.6% in 2025. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +22.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 95th percentile — a wider gap than this stock usually carries. Over the past year TMO closed higher on 50% of sessions, and it is currently 4 sessions into a rising streak.

On October specifically: over 14 years of records, TMO finished the month higher 8 of 14 times, with a median return of +1.6% and an average of +0.7%. Its strongest month historically has been July at +7.4% on average, its weakest February at -2.9%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: TMO has opened more than 2% away from the prior close in 93 of 3,268 sessions (2.8% of the time), with the largest gaps running +6.1% and -9.0%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, TMO moved an average of 0.7% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.5% and a largest of -1.6%.

All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against TMO's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of TMO's sector?

Thermo Fisher Scientific Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
82

Options Market

What is the options market pricing for TMO?

CallsPuts

For Thermo Fisher Scientific Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.77), with at-the-money implied volatility around 55.0%. The options market is pricing roughly a ±3.7% move by that expiry — a range of about $641.64–$690.78.

Put/call ratio (2026-10-16)
0.77
ATM implied volatility
55.0%
Total open interest
14,420
Expected move by 2026-10-16
±3.7% ($641.64–$690.78)

Analyst Rating Changes

Are analysts turning bullish or bearish on TMO?

Morgan Stanley most recently reiterated its rating on Thermo Fisher Scientific Inc. to Overweight on Oct 13, 2026 with a price target of $730 (from $650). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Morgan Stanley — Overweight
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 13, 2026Morgan StanleyMaintainedOverweight$650 → $730
Oct 13, 2026TD CowenMaintainedBuy$675 → $760
Oct 7, 2026BarclaysMaintainedOverweight$650 → $750
Sep 3, 2026CLSAInitiatedOutperform$748
Jul 27, 2026Piper SandlerMaintainedNeutral$510 → $600
Jul 27, 2026Morgan StanleyMaintainedOverweight$620 → $650
Jul 24, 2026RBC CapitalMaintainedSector Perform$490 → $580
Jul 24, 2026BarclaysMaintainedOverweight$625 → $650
Jul 6, 2026Evercore ISI GroupMaintainedOutperform$575 → $570
Jun 11, 2026Piper SandlerInitiatedNeutral$510
Jun 3, 2026HSBCDowngradeBuy → Hold$670 → $540
May 8, 2026Wells FargoMaintainedOverweight$675 → $615

Peers & ETF holders

TMO peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

69/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
The Lindsell Train Global Equity Fund’s third‑quarter 2026 investor letter highlighted Thermo Fisher Scientific’s solid performance amid a broader rebound in the biotech and pharmaceutical sectors. The fund noted that Thermo Fisher’s earnings growth contributed to positive gains in July and August, offset by a September pullback linked to rising bond yields. Management expressed optimism about long‑term returns, citing compelling valuations and ongoing portfolio growth. The letter positioned Thermo Fisher as a key driver of the fund’s outperformance relative to the MSCI World Index.
What did this article say?
Earlier in October, Quantum BioPharma entered a Study Start‑Up Agreement with Thermo Fisher Scientific to run a Phase 2 trial of Lucid‑MS, illustrating the company’s growing clinical research footprint. Thermo Fisher also showcased new drug development, manufacturing, and evidence‑generation solutions at CPHI Milan 2026, signaling a broader role across the drug lifecycle. These developments suggest increased revenue opportunities and reinforce TMO’s positioning as a comprehensive life‑science platform. The expanded services could attract additional clients and strengthen the company’s competitive advantage in the biopharma ecosystem.
What did this article say?
Thermo Fisher Scientific reported a strong year, with its shares rising more than 11% to date. The rally reflects a broader recovery in the life‑sciences tools sector. Analysts question whether the company’s earnings growth can sustain the premium investors are paying. The market remains cautious about future profitability, despite the current upside.
What did this article say?
Thermo Fisher Scientific (TMO) was expected to report Q3 2026 results on October 21, with analysts forecasting an adjusted EPS of $6.40, up 10.5% from the prior year. The company has consistently beat earnings estimates for the past four quarters, reinforcing its strong financial trajectory. Market analysts projected fiscal 2026 adjusted EPS of $25.13, marking a 9.9% increase from 2025. TMO’s shares had risen 21.6% over the past year, outperforming both the S&P 500 and the health care sector ETF.
What did this article say?
Thermo Fisher Scientific announced its participation in the Digital CMC Consortium, a collaboration aimed at establishing shared digital standards for Chemistry, Manufacturing, and Controls in biopharma. The consortium brings together biopharma companies, technology providers, and regulators to streamline regulatory reviews and enable digital lifecycle management. By leveraging its extensive product portfolio and global reach, Thermo Fisher positions itself as a key enabler of faster therapy development and more efficient manufacturing processes.
What did this article say?
Thermo Fisher Scientific announced a Study Start‑Up Agreement with Quantum BioPharma to conduct a Phase 2 multiple sclerosis trial for Lucid‑MS. The deal expands Thermo Fisher’s clinical research portfolio and adds a new revenue stream in a high‑growth therapeutic area. The agreement is expected to enhance the company’s pipeline positioning and support future earnings growth. The contract aligns with Thermo Fisher’s strategy to deepen its presence in advanced drug development services.
What did this article say?
Baird lifted its price target for Thermo Fisher Scientific (TMO) to $723 from $686, reflecting a more optimistic view of the company’s earnings prospects. The brokerage cited stronger revenue growth expectations and a favorable product pipeline as key drivers. The upgrade aligns with an overweight rating and a mean target of $678.17 among analysts. This adjustment signals confidence in TMO’s ability to sustain growth amid competitive pressures.
What did this article say?
Thermo Fisher Scientific’s clinical research arm signed a study agreement with Quantum BioPharma to launch a Phase 2 trial of the Lucid-MS therapy. The trial will evaluate a neuroprotective approach that targets demyelination, diverging from conventional immune‑modulating MS treatments. The partnership leverages Thermo Fisher’s expertise in CNS and MS studies to accelerate the drug’s clinical development. This collaboration signals a strategic expansion of Thermo Fisher’s contract research services into neurodegenerative therapeutics.
What did this article say?
Thermo Fisher Scientific reported that its growth momentum is being reinforced by continued innovation, strategic acquisitions, and expanding customer partnerships across the scientific and biopharma sectors. The company highlighted that organic revenue expectations for 2026 are improving, driven by broad end‑market expansion. Macro‑economic uncertainty, inflation, geopolitical tensions, and currency volatility were identified as potential risks to future performance. Despite these headwinds, the firm’s earnings have consistently beat estimates over the past four quarters, with an average surprise of 4.4%. The stock has outperformed the industry and the broader market, rallying 21.8% versus 6.6% industry growth and 16.8% S&P 500 gains.

Technical Analysis

Real-time indicators across multiple timeframes

57
NEUTRAL
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $77.89B combined position · 10 adding, 15 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy34,133,7029.29%$19.78B2026-01-29
BlackRock, Inc.▲ Buy30,919,6328.42%$15.50B2026-08-07
FMR LLC (Fidelity)▲ Buy14,084,4883.84%$7.06B2026-08-13
Morgan Stanley▼ Sell10,763,0662.93%$5.40B2026-08-13
JPMorgan Chase & Co▲ Buy8,503,5272.32%$4.31B2026-08-12
Geode Capital Management, LLC▼ Sell8,382,4012.28%$4.18B2026-08-12
Capital World Investors▼ Sell6,195,3701.69%$3.11B2026-08-12
Norges Bank▼ Sell5,087,9031.39%$2.55B2026-08-12
Capital Research Global Investors▼ Sell4,147,5451.13%$2.08B2026-08-12
Bank of America Corp▼ Sell3,895,2651.06%$1.95B2026-08-14
Northern Trust Corp▼ Sell3,328,8360.91%$1.67B2026-08-13
Goldman Sachs Group Inc▼ Sell2,957,0660.81%$1.48B2026-08-14
Fisher Asset Management, LLC▲ Buy2,915,7150.79%$1.46B2026-08-04
Invesco Ltd.▼ Sell2,179,0100.59%$1.09B2026-08-14
Viking Global Investors LP▲ Buy1,937,4150.53%$971.34M2026-08-14
AllianceBernstein L.P.▼ Sell1,849,0370.50%$908.86M2026-08-14
Wells Fargo & Company▲ Buy1,458,4310.40%$731.20M2026-08-14
Loomis Sayles & Co L P▼ Sell1,315,1850.36%$659.38M2026-08-14
Temasek Holdings (Private) Ltd▼ Sell1,163,7290.32%$583.45M2026-08-07
Farallon Capital Management LLC▲ Buy1,049,1850.29%$526.02M2026-08-14
Wellington Management Group LLP▼ Sell979,1810.27%$490.92M2026-08-14
D1 Capital Partners L.P.▲ Buy817,1230.22%$409.67M2026-08-14
Neuberger Berman Group LLC▼ Sell667,5060.18%$334.66M2026-08-13
Citigroup Inc▲ Buy650,9760.18%$326.37M2026-08-03
Janus Henderson Group plc▼ Sell660,2580.18%$324.56M2026-05-18
Q2 2026 flow:6.20M sh bought ($3.11B)4.18M sh sold ($2.09B)net +2.02M sh (+$1.02B)
Congressional Trading Activity
25 disclosed trades · ~$347.0K est. traded value · 7 buys, 18 sells
MemberChamberStateTypeAmountTradedFiled
Dan NewhouseHouseWA04▼ Sell$1K - $15K2026-07-102026-07-17
Dwight EvansHousePA03▼ Sell$1K - $15K2026-05-072026-05-15
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-312025-11-21
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-302025-11-21
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-10-302025-11-21
Valerie HoyleHouseOR04▼ Sell$1K - $15K2025-09-232025-10-10
Kelly Louise MorrisonHouseMN03▼ Sell$15K - $50K2025-08-192025-09-11
Julia LetlowHouseLA05▲ Buy$1K - $15K2025-07-252026-01-13
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-07-222025-08-13
Angus KingSenate-▼ Sell$1K - $15K2025-07-212025-08-18
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-06-102025-08-13
Valerie HoyleHouseOR04▲ Buy$1K - $15K2025-06-062025-09-12
Richard W. AllenHouseGA12▼ Sell$15K - $50K2025-05-162025-06-18
Rob BresnahanHousePA08▲ Buy$15K - $50K2025-05-152025-05-31
Thomas H. KeanHouseNJ07▲ Buy$1K - $15K2025-05-052025-06-17
Julia LetlowHouseLA05▼ Sell$1K - $15K2025-04-282026-01-13
Bruce WestermanHouseAR04▼ Sell$1K - $15K2025-04-212025-05-12
Richard W. AllenHouseGA12▼ Sell$15K - $50K2025-04-112025-05-15
Dan NewhouseHouseWA04▼ Sell$1K - $15K2025-04-112025-05-16
Rob BresnahanHousePA08▼ Sell$15K - $50K2025-04-082025-04-28
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-04-072025-05-14
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-04-072025-05-08
Greg LandsmanHouseOH01▼ Sell$1K - $15K2025-03-272025-04-08
Valerie HoyleHouseOR04▼ Sell$1K - $15K2025-03-032025-09-12